Obstructive sleep apnea (OSA) is a disease that results from loss of upper airway muscle
tone leading to upper airway collapse during sleep in anatomically susceptible persons …

Obstructive sleep apnea (OSA) is one of the most frequent chronic diseases, and comorbid
obesity occurs in more than 60% of cases. Variations in body weight influence both OSA …

Background Continuation of continuous positive airway pressure (CPAP) therapy after initial
prescription has been shown to reduce all-cause mortality versus therapy termination …

Background The dual orexin receptor antagonist daridorexant did not impact nighttime
respiratory function as assessed by the apnea/hypopnea index (AHI) and nocturnal oxygen …

Background The symptomatic response to continuous positive airway pressure (CPAP)
therapy in COPD-obstructive sleep apnea overlap syndrome (OVS) compared to OSA …

Patients with sleep apnea are usually treated with continuous positive airway pressure
(CPAP). This therapy is very effective if the patient′ s adherence is satisfactory. However …

Obstructive sleep apnoea (OSA) is a common disease in the general population, and is
associated with increased cardiovascular risk and several comorbidities. Obesity favours …

Rationale: Positive airway pressure (PAP) is the first-choice treatment for obstructive sleep
apnea (OSA). However, its real-world effectiveness is often questioned because of usage …

Obstructive sleep apnoea (OSA) was traditionally thought to be mainly caused by obesity
and upper airway crowding, and hence OSA management was not personalised according …

Intermittent hypoxia (IH) is a landmark of obstructive sleep apnea (OSA) at the core of the
cardiovascular consequences of OSA. IH triggers oxidative stress, a major underlying …